ストックスクリーナーアプリを入手
23.09
1.16%
-0.27
前日終値:
$23.36
開ける：
$23.21
24時間の取引高:
1.39M
Relative Volume:
2.88
時価総額：
$1.70B
収益：
$384.10M
当期純損益:
$-9.07M
株価収益率:
-164.93
EPS:
-0.14
ネットキャッシュフロー:
$11.10M
1週間 パフォーマンス:
-1.16%
1か月 パフォーマンス:
+17.63%
6か月 パフォーマンス:
-7.64%
1年 パフォーマンス:
+17.03%
1日の値動き範囲:
$22.83
$23.38
1週間の範囲:
$22.62
$23.86
52週間の値動き範囲:
$16.56
$28.15
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
名前
Kiniksa Pharmaceuticals International Plc
セクター
電話
(781) 431-9100
住所
23 OLD BOND STREET, FLOOR 3, LONDON
KNSA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
23.09 | 1.70B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
163.11 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.24 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.81 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-09-13 | 開始されました | Jefferies | Buy |
| 2024-05-03 | 開始されました | Wells Fargo | Overweight |
| 2020-06-29 | 繰り返されました | BofA Securities | Buy |
| 2020-04-01 | 開始されました | BofA/Merrill | Buy |
| 2019-03-11 | 開始されました | Barclays | Overweight |
| 2018-12-12 | 繰り返されました | Wedbush | Outperform |
| 2018-06-19 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Kiniksa Pharmaceuticals International Plc (KNSA) 最新ニュース
Kiniksa CFO Mark Ragosa sells shares worth $368,465 By Investing.com - Investing.com South Africa
Kiniksa CFO Mark Ragosa sells shares worth $368,465 - Investing.com India
Kiniksa pharmaceuticals CFO Mark Ragosa sells $469,923 in stock By Investing.com - Investing.com South Africa
Kiniksa pharmaceuticals CFO Mark Ragosa sells $469,923 in stock - Investing.com
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Buy Rating from Analysts at Citigroup - MarketBeat
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Michael R. Megna Sells 9,051 Shares - MarketBeat
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $36.60 Average Target Price from Analysts - MarketBeat
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells $809,277.00 in Stock - MarketBeat
Globeflex Capital L P Boosts Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Sells 17,118 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals CFO Mark Ragosa sells $809k in shares By Investing.com - Investing.com Canada
Kiniksa Pharmaceuticals CAO Michael Megna sells shares worth $203,194 By Investing.com - Investing.com Australia
Kiniksa Pharmaceuticals CAO Michael Megna sells shares worth $203,194 - Investing.com India
Kiniksa Pharmaceuticals CFO Mark Ragosa sells $809k in shares - Investing.com
Kiniksa Pharmaceuticals Executives Sell Shares - TradingView
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now - Mitrade
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now - The Motley Fool
Taking on analysts’ expectations and winning: Kiniksa Pharmaceuticals International Plc (KNSA) - SETE News
Citigroup Initiates Coverage on Kiniksa Pharmaceuticals International With Buy Rating, $40 Price Target - Marketscreener.com
Kiniksa Pharmaceuticals COO sells shares worth $261,333 - Investing.com
Kiniksa Pharmaceuticals COO sells shares worth $261,333 By Investing.com - Investing.com UK
Deeper Dive: Understanding Kiniksa Pharmaceuticals International Plc (KNSA) Through its Various Ratios - The Dwinnex
Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst - Benzinga India
Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now? - Insider Monkey
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Rhumbline Advisers - Defense World
New York State Common Retirement Fund Has $302,000 Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Sees Large Increase in Short Interest - Defense World
10 Best UK Growth Stocks to Buy Now - Insider Monkey
Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stocks to Buy Now? - Insider Monkey
Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now? - Insider Monkey
12 Best Small Cap Pharma Stocks to Buy Now - Insider Monkey
Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus.com
Kiniksa Pharmaceuticals Shifts Strategic Focus with Key Agreement Terminations and 2024 Financial Results - Defense World
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2024 Earnings Call Transcript - Insider Monkey
Kiniksa Pharmaceuticals Q4 2024 Earnings: Revenue at $122.5M, Mi - GuruFocus.com
Kiniksa issues updates on abiprubart, KPL-387, mavrilimumab - MSN
Big Pipeline Updates From Kiniksa Pharmaceuticals (NASDAQ:KNSA) - Seeking Alpha
Kiniksa to launch Phase 2/3 trial for heart drug KPL-387 - Investing.com India
Kiniksa Pharmaceuticals Swings to Q4 Loss, Revenue Increases -February 25, 2025 at 08:20 am EST - Marketscreener.com
Kiniksa to launch Phase 2/3 trial for heart drug KPL-387 By Investing.com - Investing.com South Africa
Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Total Revenue $122.5M, vs. FactSet Est of $123.4M - Marketscreener.com
Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Net Loss $-0.12 a Share, vs. FactSet Est of $-0.06 Loss - Marketscreener.com
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution - The Manila Times
Kiniksa Pharmaceuticals Reports Strong Q4 2024 Financials with ARCALYST Revenue of $417 Million and Anticipates 2025 Sales Growth - Nasdaq
Kiniksa Pharmaceuticals Announces Development of KPL-387 in - GlobeNewswire
Can Kiniksa's 79% Revenue Surge Continue as Company Shifts Pipeline Focus? - StockTitan
Can Kiniksa's New Pericarditis Drug Build on Its $800M ARCALYST Success? - StockTitan
KNSAKiniksa Pharmaceuticals International, plc Latest Stock News & Market Updates - StockTitan
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewswire
Kiniksa Pharmaceuticals COO Tessari Eben sells $273,980 in shares - MSN
Kiniksa Pharmaceuticals COO sells shares worth $273,980 - MSN
Kiniksa Pharmaceuticals International Plc (KNSA) 財務データ
収益
当期純利益
現金流量
EPS
Kiniksa Pharmaceuticals International Plc (KNSA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ragosa Mark | CHIEF FINANCIAL OFFICER |
Mar 20 '25 |
Sale |
23.11 |
15,944 |
368,466 |
23,382 |
| Ragosa Mark | CHIEF FINANCIAL OFFICER |
Mar 17 '25 |
Option Exercise |
12.97 |
11,464 |
148,688 |
34,846 |
| Ragosa Mark | CHIEF FINANCIAL OFFICER |
Mar 19 '25 |
Option Exercise |
12.97 |
8,879 |
115,161 |
32,261 |
| Ragosa Mark | CHIEF FINANCIAL OFFICER |
Mar 17 '25 |
Sale |
23.10 |
11,464 |
264,818 |
23,382 |
| Ragosa Mark | CHIEF FINANCIAL OFFICER |
Mar 19 '25 |
Sale |
23.10 |
8,879 |
205,105 |
23,382 |
3.70%
0.05%
大文字化:
|
ボリューム (24 時間):